Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 8/20 | 0.32 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13072326 | 0.88 | IDO1 (0.38) | IDO1CCRL2NR1I2CYP2C8CYP2C9 | |
| SCHEMBL15373221 | 0.88 | IDO1 (0.38) | IDO1CCRL2NR1I2CYP2C8CYP2C9 | |
| SCHEMBL3117394 | 0.84 | AAK1 (0.44) | ALDH1A1KMT2AAAK1 | |
| SCHEMBL20707013 | 0.84 | EPHX1 (0.38) | IDO1CCRL2 | |
| SCHEMBL17323219 | 0.84 | CNR2 (0.34) | SMN1; SMN2ALDH1A1PIK3CDCNR2 | |
| SCHEMBL9998907 | 0.80 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1CYP2C9CYP2C19MEN1 | |
| SCHEMBL9999019 | 0.79 | THRB (0.40) | SMN1; SMN2IDO1CCRL2NR1I2CYP2C8 | |
| SCHEMBL10150991 | 0.78 | AAK1 (0.36) | ALDH1A1PIK3CDAAK1 | |
| SCHEMBL8918660 | 0.78 | AAK1 (0.36) | ALDH1A1PIK3CDAAK1 | |
| SCHEMBL20643824 | 0.78 | AAK1 (0.36) | ALDH1A1PIK3CDAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-8673954-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8420686-B2 | Linked diimidazole antivirals | ENANTA PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | SMN1; SMN2 3741/4885ALDH1A1 201/4885IDO1 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.